Preclinical studies demonstrated that the depletion of Tregs or intrahepatic macrophages can activate peripheral CD8+ T‐cell immunity and induce intrahepatic tumor regression, suggesting the potential of liver‐directed immunotherapy [10, 11]. This evidence concerns the gene CD8A and neoplasm.